A personalised cancer vaccine has delivered encouraging results in a major clinical trial involving people with high-risk melanoma, a serious form of skin cancer. When combined with the immunotherapy drug pembrolizumab, the experimental vaccine reduced the risk of cancer recurrence or death by 42% compared with immunotherapy alone.
The findings could mark an important step forward in personalised cancer treatment. Unlike conventional vaccines designed to prevent infections, this approach is intended to help the immune system recognise and attack cancer cells using information specific to an individual patient’s tumour.
How the Personalised Cancer Vaccine Works
The experimental vaccine, known as intismeran autogene, uses mRNA technology. Doctors analyse a patient’s tumour to identify genetic changes that may produce targets for the immune system. The vaccine is then designed to help immune cells recognise those targets.
Researchers combined the vaccine with pembrolizumab, an immunotherapy medicine that helps the immune system attack cancer. The treatment was studied in patients whose high-risk melanoma had been surgically removed.
What the Clinical Trial Found
The Phase 3 trial involved 1,137 patients with high-risk melanoma. After approximately two years, around 82% of participants who received the vaccine alongside pembrolizumab remained free of recurrence, compared with about 70% of those who received pembrolizumab alone.
These results suggest that adding a personalised vaccine may improve outcomes for some patients after surgery. However, the findings relate to a specific cancer type and treatment combination, rather than cancer treatment in general.
Side Effects and Further Research
Reported side effects included fatigue, fever and pain around the injection site. Researchers are continuing to assess longer-term outcomes, and regulatory review is needed before the treatment can become widely available.
The approach is also being investigated as a possible model for developing personalised treatments for other cancers. Whether it will prove effective across different tumour types remains uncertain.
